文献速递自身免疫性与大疱性皮肤病

皮肤脆弱症的患病率及危险因素:芬兰三级医院皮肤科门诊患者的前瞻性观察研究

Prevalence of and risk factors for dermatoporosis: a prospective observational study of dermatology outpatients in a Finnish tertiary care hospital.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-10-01

该前瞻性观察研究纳入赫尔辛基大学中心医院皮肤科门诊176例60岁及以上连续就诊患者,评估皮肤脆弱症患病率及危险因素。结果显示30.7%存在皮肤脆弱症,皮损主要位于上肢(94%),以I期最常见(75.9%)。多因素分析显示皮肤脆弱症与超强效外用糖皮质激素、口服糖皮质激素、糖皮质激素联合抗凝治疗及慢性肾功能衰竭、年龄显著相关。作者承认存在选择偏倚,认为芬兰皮肤科门诊皮肤脆弱症患病率似乎与法国相当,提醒对衰弱老年患者长期使用糖皮质激素需权衡指征。

要点

  • 60岁及以上皮肤科门诊患者中皮肤脆弱症患病率为30.7%。
  • 皮损主要位于上肢(94%),I期最常见(75.9%)。
  • 超强效外用糖皮质激素、口服糖皮质激素、糖皮质激素联合抗凝及慢性肾功能衰竭、年龄与皮肤脆弱症显著相关。

核心结论

  • 作者承认研究存在选择偏倚,芬兰皮肤科门诊皮肤脆弱症患病率似乎与法国相当。
  • 作者认为这些结果促使我们对衰弱老年患者长期使用糖皮质激素的指征进行权衡。

研究设计与样本

  • 前瞻性观察研究,纳入赫尔辛基大学中心医院皮肤科门诊176例60岁及以上连续就诊患者。
  • 收集年龄、性别、就诊原因、局部或全身糖皮质激素治疗、抗血小板药物及抗凝治疗、糖尿病和慢性肾功能衰竭(肾小球滤过率< 60 mL/min/m2)等资料。
  • 记录皮肤脆弱症的存在、身体部位及分期。

主要发现

  • 30.7%的患者存在皮肤脆弱症。
  • 皮损主要位于上肢(94%),I期最常见(占病例的75.9%)。
  • 多因素分析显示皮肤脆弱症与超强效外用糖皮质激素显著相关(OR 5.34,95% CI 1.85-15.43,P = 0.002)。
  • 皮肤脆弱症与口服糖皮质激素显著相关(OR 3.22,95% CI 1.18-8.80,P = 0.022)。
  • 皮肤脆弱症与糖皮质激素联合抗凝治疗及慢性肾功能衰竭显著相关(OR 4.02,95% CI 1.34-12.01,P = 0.013),与年龄显著相关(OR 1.05,95% CI 1.01-1.10,P = 0.016)。

关键数值与推荐

  • 大疱性类天疱疮患者在本队列中皮肤脆弱症患病率最高(64%)。

临床怎么用

  • 作者认为这些结果促使我们对衰弱老年患者长期使用糖皮质激素的指征进行权衡。

局限性

  • 作者承认研究存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dermatoporosis describes the cutaneous signs and complications related to chronic cutaneous fragility related to ageing, chronic sun exposure and long-term use of topical and systemic corticosteroids. Chronic renal failure may be an additional cofactor. The prevalence of dermatoporosis is estimated around 32-37% in France among the elderly. OBJECTIVE: We evaluated the prevalence of dermatoporosis and its risk factors in outpatients who attended a consultation in the department of dermatology of Helsinki University Central Hospital. METHODS: A prospective observational study of 176 consecutive outpatients aged 60 years and older, who attended a consultation in the department of dermatology of Helsinki University Central Hospital. Data collection included age, gender, reason for consultation, local or systemic corticosteroid therapy, antiplatelet drugs and anticoagulant therapy, diabetes and chronic kidney failure (glomerular filtration rate < 60 mL/min/m2 ). The presence of dermatoporosis, location on the body and staging were collected. RESULTS: 30.7% presented dermatoporosis. Lesions were mainly located on the upper limbs (94%), and stage I was the most frequent (75.9% of the cases). Multivariate analysis revealed that dermatoporosis was significantly associated with ultrapotent topical corticosteroids (odds ratio (OR) 5.34, 95% CI 1.85-15.43, P = 0.002), oral corticosteroids (OR 3.22, 95% CI 1.18-8.80, P = 0.022), concomitant corticosteroid therapy, anticoagulant and chronic renal failure (OR 4.02, 95% CI 1.34-12.01, P = 0.013) and age (OR 1.05, 95% CI 1.01-1.10, P = 0.016). Patients with bullous pemphigoid were those with the highest prevalence of dermatoporosis in our cohort (64%). CONCLUSION: Acknowledging the selection bias in our study, the prevalence of dermatoporosis in a dermatology consultation in Finland seems as frequent as in France. These results prompt us to weigh the indications of long-term corticosteroids use in frail elderly patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kluger N, Impivaara S. Prevalence of and risk factors for dermatoporosis: a prospective observational study of dermatology outpatients in a Finnish tertiary care hospital. J Eur Acad Dermatol Venereol. 2018. PMID: 30198583. doi:10.1111/jdv.15240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。